AbbVie Inc. ABBV
$220.72▲ +1.32% 24H
Super Investor & Insider
6
Fondi che lo detengono
#123
Rank consenso
8.6%
% dei portafogli
$26.3M
Valore detenuto
| Fondo | % portaf. | Attività | Azioni | Valore |
|---|---|---|---|---|
| Mairs & Power · Mairs & Power | 0.1% | Reduce 2.45% | 45,317 | $9.9M |
| David Katz · Matrix Asset Advisors | 0.78% | Add 2.32% | 39,175 | $8.5M |
| Thomas Russo · Gardner Russo & Quinn | 0.03% | — | 12,410 | $2.7M |
| Jensen Investment Management · Jensen Investment Management | 0.05% | — | 11,144 | $2.4M |
| Dodge & Cox · Dodge & Cox | 0% | — | 10,393 | $2.3M |
| Bill Nygren · Harris Associates | 0% | — | 2,682 | $583,308 |
Fondi: 13F-HR alla SEC. Insider: acquisti (P) e vendite (S) in borsa da SEC EDGAR, ultimi 12 mesi.
About
AbbVie Inc. is a research-based biopharmaceutical company that discovers, develops, manufactures, and commercializes innovative medicines and therapies worldwide. The company maintains a strong focus on immunology, offering treatments like Humira, Skyrizi, and Rinvoq for autoimmune and inflammatory conditions in rheuma…
SectorHealthcare
ExchangeNYSE
IndustryDrug Manufacturers - General
CountryUnited States
Employees57,000
TickerABBV
Statistics
Market Cap$389.96B
Revenue (TTM)$61.16B
Net Income$4.23B
Net Margin6.9%
EPS$2.36
P/E109.64
P/S6.32
P/B-60.06
EV/EBITDA15.40
ROE-129.7%
Dividend Yield3.08%
Price$220.72
Data: Twelve Data · Revenue = mcap / P/S